查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847876

節肢動物傳播病毒感染檢測市場（依檢測類型、技術、最終用戶、樣本類型和疾病類型分類）－全球預測，2025-2032年

Arthropod-borne Viral Infections Testing Market by Test Type, Technology, End User, Sample Type, Disease Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，節肢動物傳播病毒感染檢測市場將成長至 284.7 億美元，複合年成長率為 11.19%。

主要市場統計數據
基準年 2024 121.8億美元
預計年份：2025年 135.2億美元
預測年份：2032年 284.7億美元
複合年成長率 (%) 11.19%

制定一套全面的框架，涵蓋診斷優先事項、操作要務和協作方法，以應對節肢動物傳播的病毒威脅。

節肢動物傳播的病毒感染疾病呈現出複雜且不斷變化的診斷格局，涉及臨床緊迫性、公共衛生監測和快速發展的技術三者。本執行摘要概述了目前臨床醫生、實驗室負責人和政策制定者面臨的挑戰，因為媒介傳播病原體持續需要細緻入微的診斷應對。目前的診斷重點不僅包括及時檢測病原體，還包括區分急性感染和先前感染、在流行地區進行多重鑑定以及整合監測數據以指導公共衛生干預措施。

在臨床實務中，診斷流程正在重新調整，以期在維持快速性和成本效益的同時，提高檢測的敏感度和特異性。臨床實驗室必須權衡抗體檢測（提供血清狀態資訊）、抗原檢測（提供快速照護現場能力）和分子檢測（能夠明確鑑定病原體）之間的優缺點。同時，監測系統需要來自不同終端使用者（包括醫院實驗室、參考文獻中心和學術機構）的標準化資料流，以建立可操作的流行病學資訊。

這項措施凸顯了製定一套協調一致的策略的必要性，該策略應將診斷創新與實際操作、監管要求和供應鏈考量相結合。它確立了這樣一個前提：有效應對節肢動物傳播病毒取決於在不同環境中策略性地部署檢測，謹慎選擇適合臨床問題的檢測技術，以及公共衛生機構與診斷技術研發人員之間的持續合作。

技術融合、數據互通性和彈性供應鏈如何重塑診斷方法以及公共衛生部門對蟲媒病毒疾病的應對措施

受技術創新、流行病學變化以及相關人員期望轉變的驅動，節肢動物傳播病毒的檢測格局正在發生顯著變化。核酸擴增方法的進步拓展了分子檢測的應用範圍，使其不再局限於中心實驗室，從而實現了床邊檢測平台，兼具快速出結果和強大的分析性能。同時，免疫測量方法和側向層析技術的改進也提升了抗體和抗原檢測在照護現場和分散式檢測環境中的效用。

除了檢測方法的創新之外，數據整合正在改變診斷的價值提案。即時數據流和可互通的報告系統增強了監測能力，並加快了疫情爆發的檢測速度。同時，多重檢測和綜合症檢測也日益受到重視，這些檢測能夠解決多種蟲媒病毒流行地區常見的合併感染和重疊的臨床表現。監管機構也不斷完善相關管道，以支援在緊急情況下快速部署有效的檢測方法，同時確保品質和安全標準。

供應鏈韌性和生產敏捷性已成為策略規劃的核心。診斷技術開發商正投資於多元化採購和模組化生產方式，以降低中斷風險。這些轉變反映了診斷生態系統正朝著更具適應性、網路化的模式發展，在這個生態系統中，技術能力、數據連接、監管協調和供應鏈穩健性共同作用，重塑了節肢動物傳播病毒感染的檢測和管理方式。

評估2025年關稅對診斷採購、供應鏈韌性和製造在地化策略的系統性影響

美國將於2025年開始實施的累積關稅對診斷偵測基礎設施、採購動態和供應鏈策略產生了多方面的影響。試劑、檢測盒和儀器組件等關鍵零件進口成本的上升迫使許多診斷服務提供者和實驗室重新評估籌資策略。為此，一些製造商加快了關鍵生產能力的本地化進程，而另一些製造商則重新談判了供應商合約或修改了產品設計，以減少對受關稅影響的原料的依賴。

這些調整導致整個診斷生態系統的運作發生變化。臨床實驗室和參考機構重新評估了採購週期，優先考慮與供應商建立長期夥伴關係，並加強庫存管理以減輕短期價格波動的影響。公共衛生計畫評估了採購流程，重點在於供應商多元化和疫情爆發前的緊急計畫。同時，政府採購和監管機構開展對話，力求在貿易政策目標與公共衛生需求之間取得平衡，並鼓勵在特定情況下對生命攸關的醫療用品給予豁免和臨時救濟。

關稅環境也影響了診斷公司在生產佈局和供應鏈冗餘方面的策略決策。一些公司加快了對國內或近岸生產的投資，以確保重點檢測組件的持續供應，而另一些公司則尋求聯合生產安排以分散風險。 2025年貿易政策轉變的累積影響，進一步凸顯了供應鏈透明度、彈性生產和採購管治在保障診斷能力、抵禦節肢動物傳播病毒威脅的戰略重要性。

整合細分分析，將測試類型、技術平台、檢體基質、最終用戶需求和病原體特異性診斷管道連結起來

關鍵的細分洞察闡明瞭如何選擇檢測策略和技術以協調臨床、實驗室和監測目標。在考慮檢測類型時，相關人員必須權衡抗體檢測、抗原檢測和分子檢測的互補作用。抗體檢測，包括區分IgG和IgM抗體的檢測方法，可提供有關免疫史和暴露模式的重要資訊，從而支持血清學監測和回顧性病例分類。抗原檢測，包括酵素結合免疫吸附（ELISA）抗原檢測和快速抗原檢測方法，在臨床分流和照護現場決策方面具有實際優勢。分子檢測方法，包括常規PCR、等溫擴增和即時PCR ，仍然是病原體確診和基因分型的黃金標準，對於急性病例確診和基於序列的監測至關重要。

技術選擇進一步提升了診斷效能和易用性。從化學發光免疫分析到酵素連結免疫檢測(ELISA) 和側向層析免疫檢測，免疫檢測平台提供了廣泛的規模、通量和部署選擇。化學冷光定序技術，包括 Illumina 定序和焦磷酸測序，能夠對病原體進行詳細的特性分析和基因組監測，特別適用於追蹤病毒的演化和傳播途徑。基於 PCR 的技術涵蓋了從常規 PCR 和即時PCR到等溫擴增技術，從而促進了分散式分子診斷。快速診斷測試，例如橫向流動化驗和光學免疫檢測，在臨床第一線環境中具有快速且方便的優勢。

最終用戶細分影響著採購和部署策略。學術和研發機構優先考慮支援檢測開發和基因組研究的平台，而醫院實驗室和診斷中心則更注重通量、週轉時間和與臨床工作流程的整合。參考實驗室在確診檢測和品質保證中發揮核心作用，在區域網路中提供標準化檢測和專業服務。檢體類型（血清、腦脊髓液、血漿、唾液和全血）的選擇決定了檢體處理通訊協定、檢測靈敏度和臨床效用，從而為每種疾病選擇特定的檢體基質。最後，屈公病、登革熱、西尼羅河病毒、黃熱病和茲卡等疾病類型的細分決定了診斷演算法。有些病原體在急性期需要分子確診，而有些病原體則主要依賴血清學結果進行後期診斷和監測。

了解這些多層次細分的動態將使決策者能夠根據臨床需求、監測目標和操作能力來客製化診斷服務，並認知到測試類型、技術、最終用戶、樣本類型和目標疾病之間的互通性和互補性。

世界各地不同的診斷需求和基礎設施現狀將影響技術採用、監測重點和區域實施方法。

區域動態影響診斷策略的優先排序和實施。在美洲，公共衛生機構和實驗室網路正面臨著都市區和農村地區多樣化的流行病學壓力，因此需要靈活的診斷方法，將快速篩檢與有針對性的確診檢測相結合。需求促進因素包括疫情應對準備、跨境監測以及維持對共同流行的蟲媒病毒的檢測能力。因此，重點在於投資於能夠擴展並適應不斷變化的病例數，同時通常也支援綜合報告系統的平台。

歐洲、中東和非洲各地醫療保健系統和資源環境的差異導致了不同的技術應用模式。位於城市中心和參考網路中的大型實驗室傾向於利用先進的分子和定序技術進行病原體精確鑑定，而分散的醫療機構則優先考慮經濟高效的快速診斷和完善的品質保證系統。該地區的監測重點通常在於加強樣本發放管道和協調檢體流程，以支援及時發現疫情和促進跨區域合作。

在亞太地區，某些地區蟲媒病毒的流行以及檢測能力的快速發展，推動了對多重診斷的高需求，並促使各國大力投資照護現場解決方案。擁有成熟工業基礎和製造能力的國家正在推動國內生產和技術轉讓，以增強自主研發能力；而其他國家則致力於建立實驗室網路和加強培訓，以擴大分子檢測能力。根據不同地區的具體情況，基礎設施、法規環境和流行病學之間的相互作用將決定哪些技術和交付模式最為可行。

診斷公司之間的競爭動態和策略舉措，重點在於產品組合廣度、夥伴關係、監管準備和供應鏈敏捷性。

在節肢動物傳播病毒檢測領域，企業層面的動態動態揭示了幾個相互交織的主題，這些主題正在影響企業的競爭定位和創新軌跡。在該領域，各公司都在投資涵蓋快速抗原檢測、高通量免疫測量和分子平台等綜合產品系列，以滿足臨床和監測環境中的各種應用需求。策略夥伴關係和共同開發契約已成為加速檢測檢驗、拓展分銷管道以及整合互補技術能力的常用途徑。

製造商日益重視品質系統、法規遵循和上市後監測，以確保效用並贏得實驗室客戶的信任。為了減少停機時間並最佳化各種環境下的偵測效能，企業正著力完善客戶支援體系，包括培訓、能力驗證和遠距離診斷。此外，具備定定序和生物資訊能力的公司正在拓展服務，將診斷結果與可操作的流行病學資訊結合，從而增強其對公共衛生客戶和大型診斷網路的價值提案。

供應鏈最佳化和製造敏捷性仍然是企業競爭優勢的關鍵。擁有多元化供應商基礎、近岸生產選擇以及靈活的製造外包關係的企業，能夠更好地應對採購中斷和政策變化。此外，隨著診斷技術日益融入更廣泛的醫療資訊生態系統，對資料互通性、雲端彙報和網路安全措施的投資也逐漸成為業界標準。

診斷領域領導者可採取切實可行的策略步驟和營運重點，以加強其產品組合、供應鏈、監管溝通和數據整合。

針對行業領導者的實際建議著重於使技術選擇與營運實際情況和策略韌性相契合。優先考慮均衡的產品組合策略，整合快速抗原解決方案、強大的免疫檢測平台和便利的分子診斷技術，以滿足急性臨床需求、血清學監測和確證檢測要求。在產品多樣化的基礎上，輔以服務導向能力，例如培訓、能力驗證計劃和遠端技術支持，以促進產品應用並在各種用戶環境中保持品質。

投資於供應鏈透明度和生產靈活性，以緩解防控措施帶來的成本壓力和物流中斷。考慮對關鍵試劑和組件採用近岸或冗餘生產安排，並建立策略供應商夥伴關係，以確保生產連續性。透過採用標準化報告表格和安全資料傳輸通訊協定，增強資料互通性，確保診斷結果能夠有效為公共衛生監測和臨床決策支援系統提供資訊。

我們正積極與監管機構合作，簡化緊急診斷的檢驗流程，並確保在疫情爆發期間有條件進入。我們正在擴大與公共衛生實驗室、學術機構和參考網路的舉措，以驗證不同檢體類型和疾病背景下的檢測方法。最後，我們正在建立持續學習機制，收集真實世界的績效數據和相關人員的回饋，以指導產品迭代改進和服務提升。

透過結合專家訪談、技術文獻綜述和多層次品質保證的穩健混合方法檢驗研究結果。

本報告的調查方法結合了三管齊下的證據收集、專家諮詢和嚴格的品管，以確保分析的可靠性。主要研究包括對臨床實驗室主任、分子和免疫檢測專家、公共衛生專業人員以及採購專家進行結構化訪談，以獲取關於各環境下營運限制、技術偏好和實施障礙的第一手觀點。次要研究資料包括同行評審文獻、監管指導文件、技術白皮書和公開的監測資料集，用於為主要研究成果提供背景資訊並檢驗技術論點。

分析過程包括建立一個系統框架以整合不同的資料流，隨後進行定性綜合分析，以突出主題優先事項，例如檢測選擇標準、檢體處理注意事項和供應鏈脆弱性。品質保證措施包括將訪談結果與已記錄的性能特徵進行交叉檢驗、由獨立專家進行迭代審查以及一致性檢查，以確保術語的準確性和調查方法的透明度。我們也承認存在一些局限性，例如區域報告實踐的差異以及政策環境的變化可能會影響實施結果。在條件允許的情況下，我們著重強調研究觀察的相對優先順序和操作意義，而非絕對指標，以便為實驗室負責人和衛生計畫管理人員提供可操作的決策支援。

戰略要務綜合強調技術整合、系統韌性和數據主導的協作方法，以實現持續的診斷準備。

總之，針對節肢動物傳播病毒感染疾病的診斷應對正處於曲折點，其特點是技術能力的快速提升、對供應鏈韌性的重視以及對數據驅動型監測日益成長的期望。有效的策略取決於整合互補的檢測類型——抗體檢測、抗原檢測和分子檢測——同時根據不同的最終用戶和檢體情況選擇合適的技術。政策制定者和採購負責人必須在快速取得診斷結果和長期系統永續性之間取得平衡，優先考慮靈活的生產方式和可靠的供應。

相關人員應將互通性和數據整合視為現代診斷生態系統的核心支柱，從而能夠將檢測結果快速轉化為公共衛生行動。透過投資培訓、品質系統和協作檢驗工作，該領域可以提高診斷信心，並更好地應對未來蟲媒病毒帶來的挑戰。展望未來，結合技術創新、嚴謹營運和跨部門合作的適應性策略對於在最關鍵的時刻和地點提供及時、準確和可操作的診斷資訊至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合多重PCR檢測板，用於同時檢測登革熱、屈公病和茲卡病毒
  • 推出可攜式即時診斷設備，用於檢測蟲媒病毒。
  • 擴大與智慧型手機連接的蚊媒病毒家用檢測套組的範圍
  • 實施人工智慧驅動的預測分析平台，用於即時疫情監測和檢測優先排序
  • 開發新一代血清學檢測方法，以區分地方性流行區中存在交叉反應的黃病毒抗體
  • 診斷公司與世界衛生組織夥伴關係，在資源匱乏地區進行可擴展的蟲媒病毒檢測。
  • 監管部門的核准加速了用於大規模蟲媒病毒篩檢的高通量自動化平台的商業化進程
  • 奈米孔定序技術在蚊媒病毒現場直接RNA鑑定的研究進展
  • 建立節肢動物傳播病毒監測實驗室網路，並增加政府對基因組監測的資助。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依檢測類型分類的節肢動物傳播病毒感染檢測市場

  • 抗體檢測
    • IgG抗體
    • IgM抗體
  • 抗原檢測
    • ELISA抗原
    • 快速抗原
  • 分子檢測
    • 常規PCR
    • 等溫擴增
    • 即時PCR

9. 按技術分類的節肢動物傳播病毒感染檢測市場

  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 側向流動免疫檢測
  • 下一代定序
    • Illumina定序
    • 焦磷酸測序
  • 基於PCR的技術
    • 常規PCR
    • 等溫擴增
    • 即時PCR
  • 快速診斷測試
    • 橫向流動化驗
    • 光學免疫檢測

第10章 依最終用戶分類的節肢動物傳播病毒感染檢測市場

  • 學術機構
  • 診斷中心
  • 醫院檢查室
  • 參考實驗室
  • 研究所

第11章 依樣本類型分類的節肢動物傳播病毒感染檢測市場

  • 血清
  • 腦脊髓液
  • 電漿
  • 唾液
  • 全血

第12章 依疾病類型分類的節肢動物傳播病毒感染檢測市場

  • 屈公病
  • 登革熱
  • 西尼羅河熱
  • 黃熱病
  • 茲卡熱

13. 各地區節肢動物傳播病毒感染檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 節肢動物傳播病毒感染檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國節肢動物傳播病毒感染檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • DiaSorin SpA
    • Bio-Rad Laboratories, Inc.
    • Abnova Corporation
    • AdvaCare Pharma
    • Chembio Diagnostics, Inc.
    • EUROIMMUN AG by PerkinElmer Inc.
Product Code: MRR-4103B31E09C0

The Arthropod-borne Viral Infections Testing Market is projected to grow by USD 28.47 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.18 billion
Estimated Year [2025] USD 13.52 billion
Forecast Year [2032] USD 28.47 billion
CAGR (%) 11.19%

Comprehensive framing of diagnostic priorities, operational imperatives, and collaborative approaches to address arthropod-borne viral threats

Arthropod-borne viral infections present a complex and evolving diagnostic landscape that intersects clinical urgency, public health surveillance, and rapid technological advancement. The introduction to this executive summary frames the contemporary challenges faced by clinicians, laboratory leaders, and policymakers as vector-borne pathogens continue to demand nuanced diagnostic responses. Diagnostic priorities now include not only timely pathogen detection but also differentiation between acute and past infections, multiplexed identification in co-endemic settings, and integration of surveillance data to guide public health interventions.

Across clinical environments, diagnostic workflows are being rebalanced to achieve higher sensitivity and specificity while preserving speed and cost-effectiveness. Laboratories must weigh the trade-offs among antibody assays that provide serostatus context, antigen tests that offer rapid point-of-care functionality, and molecular modalities that deliver definitive pathogen identification. Concurrently, surveillance systems require standardized data streams from diverse end users such as hospital laboratories, reference centers, and academic institutions to construct actionable epidemiologic intelligence.

This introduction underscores the need for cohesive strategies that align diagnostic innovation with operational realities, regulatory requirements, and supply chain considerations. It establishes the premise that effective responses to arthropod-borne viruses will depend on strategic deployment of tests across settings, careful selection of technologies appropriate to clinical questions, and continuous collaboration between public health authorities and diagnostic developers.

How technological convergence, data interoperability, and resilient supply chains are reshaping diagnostics and public health responses to arboviral disease

The landscape for arthropod-borne viral testing is undergoing transformative shifts driven by technological innovation, changing epidemiology, and evolving stakeholder expectations. Advances in nucleic acid amplification methods have expanded the practicality of molecular testing beyond centralized laboratories, enabling near-patient platforms that combine shortened time-to-result with robust analytical performance. At the same time, improvements in immunoassay formats and lateral flow designs have enhanced the utility of antibody and antigen testing in both point-of-care and decentralized settings.

Beyond assay innovation, data integration is altering diagnostic value propositions. Real-time data streams and interoperable reporting systems strengthen surveillance capabilities and accelerate outbreak detection. This trend is complemented by an increased emphasis on multiplexing and syndromic panels that can resolve coinfections and overlapping clinical presentations common in regions with multiple circulating arboviruses. Regulatory authorities are also refining pathways to support rapid deployment of validated tests during emergent situations while maintaining quality and safety standards.

Supply chain resilience and manufacturing agility have become central to strategic planning. Diagnostic developers are investing in diversified sourcing and modular production approaches to mitigate disruptions. Collectively, these shifts reflect a move toward more adaptive, networked diagnostic ecosystems where technological performance, data connectivity, regulatory alignment, and supply chain robustness converge to reshape how arthropod-borne viral infections are detected and managed.

Assessing the systemic consequences of 2025 tariff measures on diagnostics procurement, supply chain resilience, and manufacturing localization strategies

The introduction of cumulative tariffs by the United States in 2025 has exerted multifaceted effects across diagnostic testing infrastructure, procurement dynamics, and supply chain strategies. Rising import costs for key components such as reagents, assay cartridges, and instrument subassemblies have compelled many diagnostic providers and laboratories to reassess sourcing strategies. In response, some manufacturers accelerated localization of critical production capacity, while others renegotiated supplier contracts or adapted product designs to reduce reliance on tariff-impacted inputs.

These adjustments have translated into operational changes across the diagnostic ecosystem. Clinical laboratories and reference facilities re-evaluated procurement cycles, prioritizing long-term supplier partnerships and inventory management practices that buffer short-term price volatility. Public health programs assessing procurement for outbreak preparedness emphasized supplier diversity and contingency planning. At the same time, government procurement agencies and regulatory bodies engaged in dialogue to balance trade policy objectives with public health imperatives, encouraging exemptions or temporary relief for life-critical medical goods in certain circumstances.

The tariff environment also influenced strategic decision-making for diagnostic companies considering investments in manufacturing footprint and supply chain redundancy. Some organizations accelerated investment in domestic or near-shore production to ensure continuity for high-priority assay components, while others pursued collaborative manufacturing agreements to distribute risk. Ultimately, the cumulative impact of trade policy shifts in 2025 reinforced the strategic importance of supply chain visibility, flexible manufacturing, and procurement governance in safeguarding diagnostic readiness for arthropod-borne viral threats.

Integrated segmentation analysis linking test types, technology platforms, specimen matrices, end-user requirements, and pathogen-specific diagnostic pathways

Key segmentation insights illuminate how testing strategies and technology choices must be tailored to clinical, laboratory, and surveillance objectives. When considering test type, stakeholders must navigate the complementary roles of antibody testing, antigen testing, and molecular testing. Antibody testing, including assays that differentiate IgG from IgM antibodies, offers critical information about immune history and exposure patterns, which supports serosurveillance and retrospective case classification. Antigen testing, encompassing enzyme-linked immunosorbent (ELISA) antigen formats and rapid antigen approaches, delivers practical benefits for immediate clinical triage and point-of-care decision-making. Molecular testing modalities such as conventional PCR, isothermal amplification, and real-time PCR remain the gold standard for definitive pathogen detection and genotyping, and are pivotal for acute case confirmation and sequence-based surveillance.

Technology choices further refine diagnostic performance and operational fit. Immunoassay platforms-ranging from chemiluminescent immunoassays to ELISA and lateral flow immunoassays-provide scale, throughput, and diverse deployment options. Next generation sequencing technologies, including Illumina sequencing and pyrosequencing, enable in-depth pathogen characterization and genomic surveillance, particularly valuable for tracking viral evolution and transmission pathways. PCR-based technologies span conventional and real-time PCR as well as isothermal amplification techniques that facilitate decentralized molecular diagnostics. Rapid diagnostic tests, represented by lateral flow assays and optical immunoassays, deliver speed and ease-of-use for frontline settings.

End user segmentation shapes procurement and implementation strategies. Academic institutions and research institutes prioritize platforms that support method development and genomic studies, whereas hospital laboratories and diagnostic centers emphasize throughput, turnaround time, and integration with clinical workflows. Reference laboratories play a central role in confirmatory testing and quality assurance, supplying standardized testing and specialized services to regional networks. Sample type considerations-blood serum, cerebrospinal fluid, plasma, saliva, and whole blood-determine specimen handling protocols, assay sensitivity, and clinical utility, with specific sample matrices favored for different disease presentations. Finally, disease type segmentation across chikungunya, dengue, West Nile, yellow fever, and Zika dictates diagnostic algorithms; some pathogens necessitate molecular confirmation during the acute phase while others rely heavily on serologic interpretation for later-stage diagnosis and surveillance.

Understanding these layered segmentation dynamics enables decision-makers to align diagnostic offerings to clinical needs, surveillance goals, and operational capabilities while recognizing the interoperability and complementarity among test types, technologies, end users, sample types, and disease targets.

Regional diagnostic imperatives and infrastructure realities shaping technology adoption, surveillance priorities, and localized implementation approaches across global regions

Regional dynamics affect how diagnostic strategies are prioritized and operationalized. In the Americas, public health agencies and laboratory networks contend with diverse epidemiologic pressures across urban and rural contexts, necessitating flexible diagnostics that combine rapid screening with centralized confirmatory testing. Demand drivers include outbreak response readiness, cross-border surveillance, and the need to maintain laboratory capacity for co-circulating arboviruses. Consequently, investments often emphasize platforms that can scale and adapt to shifting caseloads while supporting integrated reporting systems.

Across Europe, the Middle East & Africa, heterogeneous healthcare systems and resource environments create differentiated adoption patterns. High-capacity laboratories in urban centers and reference networks tend to leverage advanced molecular and sequencing technologies for precise pathogen characterization, whereas decentralized settings prioritize cost-effective rapid diagnostics and robust quality assurance programs. Surveillance priorities in this region frequently focus on strengthening sample referral pathways and harmonizing diagnostic algorithms to support timely outbreak detection and cross-jurisdictional collaboration.

In the Asia-Pacific region, the combination of endemic arboviral transmission in certain geographies and rapidly evolving laboratory capabilities drives both high demand for multiplexed diagnostics and active investment in point-of-care solutions. Countries with established industrial bases and manufacturing capabilities pursue domestic production and technology transfer to support self-reliance, while others focus on building laboratory networks and enhancing training to expand molecular testing capacity. Across regions, the interplay between infrastructure, regulatory environments, and epidemiology shapes which technologies and implementation models are most viable.

Competitive dynamics and strategic maneuvers among diagnostic firms focusing on portfolio breadth, partnerships, regulatory readiness, and supply chain agility

Company-level dynamics in the arthropod-borne viral testing space reveal several converging themes that influence competitive positioning and innovation trajectories. Across the sector, firms are investing in integrated product portfolios that span rapid antigen assays, high-throughput immunoassays, and molecular platforms to address diverse use cases across clinical and surveillance settings. Strategic partnerships and cooperative development agreements have become common pathways to accelerate assay validation, expand distribution channels, and combine complementary technical capabilities.

Manufacturers are increasingly focused on quality systems, regulatory preparedness, and post-market surveillance to ensure sustained clinical utility and trust among laboratory customers. There is a notable emphasis on formalizing customer support infrastructures, including training, proficiency testing, and remote diagnostics to reduce downtime and optimize assay performance in varied settings. In addition, firms with capabilities in sequencing and bioinformatics are expanding offerings that link diagnostic outputs to actionable epidemiologic intelligence, thereby enhancing the value proposition for public health clients and large diagnostic networks.

Supply chain optimization and manufacturing agility remain competitive differentiators. Organizations that have established diversified supplier bases, near-shore production options, and flexible contract manufacturing relationships are better positioned to navigate procurement disruptions and policy shifts. Finally, investment in data interoperability, cloud-enabled reporting, and cybersecurity measures is becoming a standard expectation as diagnostics increasingly feed into broader health information ecosystems.

Practical strategic steps and operational priorities for diagnostic leaders to strengthen portfolios, supply chains, regulatory engagement, and data integration

Actionable recommendations for industry leaders emphasize aligning technological choices with operational realities and strategic resilience. Prioritize a balanced portfolio strategy that integrates rapid antigen solutions, robust immunoassay platforms, and accessible molecular diagnostics to cover acute clinical needs, serosurveillance objectives, and confirmatory testing requirements. Complement product diversification with service-oriented capabilities such as training, proficiency programs, and remote technical support to enhance adoption and sustain quality performance across user settings.

Invest in supply chain transparency and manufacturing flexibility to mitigate policy-driven cost pressures and logistical disruptions. Consider near-shore or redundant production arrangements for critical reagents and components, and cultivate strategic supplier partnerships to preserve continuity. Strengthen data interoperability by adopting standardized reporting formats and secure data transmission protocols so diagnostic outputs can effectively inform public health surveillance and clinical decision support systems.

Engage proactively with regulatory authorities to streamline validation pathways for emergent diagnostics and to secure conditional access during outbreak scenarios. Expand collaborative initiatives with public health laboratories, academic institutions, and reference networks to validate assays across diverse specimen types and disease contexts. Finally, embed a continuous learning cycle that captures real-world performance data and stakeholder feedback to guide iterative product improvements and service enhancements.

Robust mixed-methods approach combining primary expert interviews, secondary technical literature synthesis, and multi-stage quality assurance to validate insights

The research methodology underpinning this report combines triangulated evidence gathering, expert consultation, and rigorous quality controls to ensure analytic robustness. Primary research included structured interviews with clinical laboratory directors, molecular and immunoassay subject-matter experts, public health practitioners, and procurement professionals, enabling firsthand perspectives on operational constraints, technology preferences, and implementation barriers across settings. Secondary research sources comprised peer-reviewed literature, regulatory guidance documents, technical white papers, and publicly available surveillance datasets to contextualize primary insights and validate technical assertions.

Analytic processes applied systematic framework mapping to reconcile divergent data streams, followed by qualitative synthesis to surface thematic priorities such as assay selection criteria, specimen handling considerations, and supply chain vulnerabilities. Quality assurance measures included cross-validation of interview findings with documented performance characteristics, iterative review by independent experts, and consistency checks to ensure terminological precision and methodological transparency. Limitations are acknowledged, including variability in regional reporting practices and evolving policy environments that may affect implementation outcomes. Wherever possible, findings were framed to highlight relative priorities and operational implications rather than absolute measures, supporting actionable decision-making by laboratory leaders and health program managers.

Synthesis of strategic imperatives underscoring technology integration, system resilience, and collaborative data-driven approaches for sustained diagnostic readiness

In conclusion, the diagnostic response to arthropod-borne viral infections is at an inflection point, characterized by accelerating technological capability, heightened emphasis on supply chain resilience, and intensifying expectations for data-driven surveillance. Effective strategies will hinge on integrating complementary test types-antibody, antigen, and molecular-while matching technology selection to the needs of diverse end users and specimen contexts. Policymakers and procurement leaders must balance rapid access to diagnostics with long-term system sustainability, prioritizing flexible manufacturing and secure supply arrangements.

Stakeholders should also embrace interoperability and data integration as central pillars of modern diagnostic ecosystems, enabling rapid translation of laboratory findings into public health action. By investing in training, quality systems, and collaborative validation efforts, the sector can improve diagnostic reliability and readiness for future arboviral challenges. Looking forward, adaptive strategies that combine technological innovation, operational rigor, and cross-sector collaboration will be essential to deliver timely, accurate, and actionable diagnostic information where and when it matters most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multiplex PCR panels enabling simultaneous detection of dengue chikungunya and Zika viruses
  • 5.2. Adoption of portable point-of-care diagnostic devices with CRISPR-based arboviral detection technology
  • 5.3. Expansion of at-home test kits for mosquito-borne virus screening with smartphone connectivity
  • 5.4. Implementation of AI-driven predictive analytics platforms for real-time outbreak surveillance and testing prioritization
  • 5.5. Development of next-generation serological assays differentiating cross-reactive flavivirus antibodies in endemic regions
  • 5.6. Partnerships between diagnostic companies and global health organizations for scalable arboviral testing in resource-limited settings
  • 5.7. Regulatory approvals accelerating commercialization of high-throughput automated platforms for large-scale arbovirus screening
  • 5.8. Research advances in nanopore sequencing for direct RNA identification of emerging mosquito-borne viruses in field settings
  • 5.9. Increased government funding for establishing sentinel testing networks and genomic surveillance of arthropod-borne viruses

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Arthropod-borne Viral Infections Testing Market, by Test Type

  • 8.1. Antibody Testing
    • 8.1.1. IgG Antibody
    • 8.1.2. IgM Antibody
  • 8.2. Antigen Testing
    • 8.2.1. Elisa Antigen
    • 8.2.2. Rapid Antigen
  • 8.3. Molecular Testing
    • 8.3.1. Conventional PCR
    • 8.3.2. Isothermal Amplification
    • 8.3.3. Real Time PCR

9. Arthropod-borne Viral Infections Testing Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. Chemiluminescent Immunoassay
    • 9.1.2. Elisa
    • 9.1.3. Lateral Flow Immunoassay
  • 9.2. Next Generation Sequencing
    • 9.2.1. Illumina Sequencing
    • 9.2.2. Pyrosequencing
  • 9.3. PCR Based Technologies
    • 9.3.1. Conventional PCR
    • 9.3.2. Isothermal Amplification
    • 9.3.3. Real Time PCR
  • 9.4. Rapid Diagnostic Test
    • 9.4.1. Lateral Flow Assay
    • 9.4.2. Optical Immunoassay

10. Arthropod-borne Viral Infections Testing Market, by End User

  • 10.1. Academic Institutions
  • 10.2. Diagnostic Centers
  • 10.3. Hospital Laboratories
  • 10.4. Reference Laboratories
  • 10.5. Research Institutes

11. Arthropod-borne Viral Infections Testing Market, by Sample Type

  • 11.1. Blood Serum
  • 11.2. Cerebrospinal Fluid
  • 11.3. Plasma
  • 11.4. Saliva
  • 11.5. Whole Blood

12. Arthropod-borne Viral Infections Testing Market, by Disease Type

  • 12.1. Chikungunya
  • 12.2. Dengue
  • 12.3. West Nile
  • 12.4. Yellow Fever
  • 12.5. Zika

13. Arthropod-borne Viral Infections Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Arthropod-borne Viral Infections Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Arthropod-borne Viral Infections Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd.
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. bioMerieux SA
    • 16.3.5. DiaSorin S.p.A.
    • 16.3.6. Bio-Rad Laboratories, Inc.
    • 16.3.7. Abnova Corporation
    • 16.3.8. AdvaCare Pharma
    • 16.3.9. Chembio Diagnostics, Inc.
    • 16.3.10. EUROIMMUN AG by PerkinElmer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ARTHROPOD-